Probably, the combination therapy or personalised treatments targeting at FATP2 and lipocalin-2, together with metformin, might be the solutions to attenuate steatotic graft injury and subsequently reduce cancer recurrence after transplantation. This evidence concerns the gene LCN2 and cancer.